Antidepressant based on a psychedelic toad shows early promise
A psychedelic-like therapy posted encouraging early data, as regulators cleared the drug — not a hallucinogenic — for at-home testing.| STAT
Bausch Health recently stopped participating in Medicaid and a federal government drug discount program known as 340B| STAT
The U.S. has ceded its leadership in critical industries before. It must not do so with China and biotech now, writes the president and CEO of Biocom California.| STAT
A psychedelic-like therapy posted encouraging early data, as regulators cleared the drug — not a hallucinogenic — for at-home testing.| STAT
UnitedHealth is making a big change to its doctor strategy in an effort to improve financial results.| STAT
Eli Lilly announced a partnership with chipmaker NVIDIA to build what it claims will be the “most powerful supercomputer owned and operated by a pharmaceutical company.”| STAT
Bausch Health has exited Medicaid and a federal government drug discount scheme known as 340B, a step that suggests more drugmakers may do the same.| STAT
The number of people using injectable obesity treatments is increasing rapidly, and it is leading to declines in obesity, according to a new survey| STAT
The Trump administration is preparing a new probe into drug-pricing practices among U.S. trading partners, laying the ground for fresh tariffs| STAT
Enhertu can help patients with breast cancer when given earlier in the disease, according to data presented at the ESMO Conference 2025.| STAT
The Trump administration has proposed a pilot initiative to address controversy over the 340B drug discount program.| STAT
